Tennessee Medicaid demonstration approved by the Trump Administration and involving capped federal spending will likely be in the cross hairs of the federal agency review and possible withdrawal ordered by President Biden. But it's unclear whether the new Administration will also object to the demonstration's closed formulary.
President Biden directed federal agencies to review all demonstrations and waivers issued by the Trump Administration that “may reduce coverage under or otherwise undermine” Medicaid or the Affordable Care Act in an executive order signed 28 January.
After the review, federal agencies should “consider whether to suspend, revise, or rescind – and, as applicable, publish for notice and comment proposed rules suspending,
The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.
President Trump's ongoing interest in the policy, which would ensure the US government pays no more for prescription drugs than the lowest price available in comparable countries, continues to gain attention.
Manufacturers have supported the proposed shift in oversight authority, which could create a more pharma-friendly environment in the drug discount program, but uncertainty remains.
Coverage data from the two programs suggest Medicare beneficiaries may be more disappointed than Medicaid enrollees by the Trump Administration’s decision not to mandate the programs cover obesity drugs.
England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.
European pharma trade associations EFPIA and EUCOPE outline their respective views on how the EU’s pharma legislation overhaul should tackle antimicrobial resistance, and why transferable exclusivity vouchers alone will not suffice as incentives.
Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.
